PE20080742A1 - Perfil genico y procedimiento de identificacion - Google Patents
Perfil genico y procedimiento de identificacionInfo
- Publication number
- PE20080742A1 PE20080742A1 PE2007000676A PE2007000676A PE20080742A1 PE 20080742 A1 PE20080742 A1 PE 20080742A1 PE 2007000676 A PE2007000676 A PE 2007000676A PE 2007000676 A PE2007000676 A PE 2007000676A PE 20080742 A1 PE20080742 A1 PE 20080742A1
- Authority
- PE
- Peru
- Prior art keywords
- immunotherapy
- gene profile
- cancer
- identification procedure
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
REFERIDA A UN PERFIL GENICO INDICATIVO DE UN PROBABILIDAD AUMENTADA DE UNA RESPUESTA A UNA INMUNOTERAPIA QUE COMPRENDE LA REGULACION DIFERENCIAL DE AL MENOS UN GEN DE ACTIVACION INMUNE, DONDE LA INMUNOTERAPIA ES UNA INMUNOTERAPIA DE CANCER ESPECIFICA DEL ANTIGENO MAGE QUE SON ANTIGENOS CODIFICADOS POR LA FAMILIA DE GENES DE ANTIGENO ASOCIADOS A MELANOMA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE IDENTIFICACION DE DICHO PERFIL GENICO Y A UN KIT. EL PERFIL GENICO DE UN PACIENTE, EL PROCEDIMIENTO DE IDENTIFICACION DEL PERFIL GENICO Y EL KIT SON UTILES EN LA IDENTIFICACION DE PACIENTES CON CANCER QUE ES PROBABLE QUE RESPONDAN A LA INMUNOTERAPIA APROPIADA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0610949A GB0610949D0 (en) | 2006-06-02 | 2006-06-02 | Method |
GB0700761A GB0700761D0 (en) | 2007-01-15 | 2007-01-15 | Method |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080742A1 true PE20080742A1 (es) | 2008-08-06 |
Family
ID=38801855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000676A PE20080742A1 (es) | 2006-06-02 | 2007-05-31 | Perfil genico y procedimiento de identificacion |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100021424A1 (es) |
EP (23) | EP2390364A1 (es) |
JP (1) | JP2009538607A (es) |
KR (1) | KR20090017655A (es) |
AR (1) | AR061136A1 (es) |
AU (1) | AU2007256383B2 (es) |
BR (1) | BRPI0712497A2 (es) |
CA (1) | CA2653949A1 (es) |
CL (1) | CL2007001571A1 (es) |
EA (1) | EA200802242A1 (es) |
ES (1) | ES2539042T3 (es) |
MX (1) | MX2008015372A (es) |
PE (1) | PE20080742A1 (es) |
TW (1) | TW200817680A (es) |
WO (1) | WO2007140958A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247580A1 (en) * | 2007-11-30 | 2010-09-30 | Thierry Coche | Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy |
GB0816867D0 (en) * | 2008-09-15 | 2008-10-22 | Glaxosmithkline Biolog Sa | Method |
GB2466025A (en) * | 2008-12-08 | 2010-06-09 | Univ Francois Rabelais De Tour | C3/ITGAM polymorphisms and cancer prognosis |
GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
US20120258076A1 (en) * | 2009-12-16 | 2012-10-11 | Hitachi Chemical Research Center, Inc. | Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers |
EP2380991A1 (en) | 2010-04-20 | 2011-10-26 | Universitätsklinikum Hamburg-Eppendorf | Method of determining the metastatic potential of a tumor |
CA2811015A1 (en) * | 2010-09-15 | 2012-03-22 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
KR101287600B1 (ko) * | 2011-01-04 | 2013-07-18 | 주식회사 젠큐릭스 | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 |
US9926604B2 (en) | 2011-10-14 | 2018-03-27 | The Regents Of The University Of California | Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same |
JP6923291B2 (ja) * | 2012-07-12 | 2021-08-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 少なくとも7個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法 |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
WO2016004423A1 (en) * | 2014-07-03 | 2016-01-07 | University Of Virginia Patent Foundation | Systems and methods for identifying and profiling muscle patterns |
US20170298443A1 (en) * | 2014-09-25 | 2017-10-19 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
JP6489900B2 (ja) * | 2015-03-30 | 2019-03-27 | 株式会社ジャパンディスプレイ | 入力装置及び表示装置 |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
WO2017011623A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
US11028443B2 (en) | 2015-08-31 | 2021-06-08 | Showa Denko Materials Co., Ltd. | Molecular methods for assessing urothelial disease |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
GB201908565D0 (en) * | 2019-06-14 | 2019-07-31 | Cray Innovation Ab | Method of stratifying subjects into sub-groups for therapeutic treatment |
CN114540504B (zh) * | 2022-04-27 | 2022-07-08 | 广州万德基因医学科技有限公司 | 用于预测肺鳞癌患者免疫疗效的标志物组及*** |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1001034B (el) * | 1989-07-21 | 1993-03-31 | Ortho Pharma Corp | Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
DK1659179T3 (da) | 1998-02-05 | 2011-10-10 | Glaxosmithkline Biolog Sa | Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination |
AU773204C (en) | 1998-08-10 | 2005-05-19 | Antigenics Llc | Compositions of CPG and saponin adjuvants and methods thereof |
IL144371A0 (en) | 1999-01-29 | 2002-05-23 | Corixa Corp | Her-2/neu fusion proteins |
ATE342727T1 (de) | 1999-03-11 | 2006-11-15 | Glaxosmithkline Biolog Sa | Verwendung von casb618 polynucleotide und polypeptide |
EP2322210A1 (en) | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
PT1650221E (pt) | 2000-02-23 | 2012-09-05 | Glaxosmithkline Biolog Sa | Novos compostos |
AUPR077900A0 (en) * | 2000-10-13 | 2000-11-09 | Tvw Telethon Institute For Child Health Research | Immunodiagnosis |
US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
KR20030092003A (ko) * | 2001-02-26 | 2003-12-03 | 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) | 인터페론 조절 인자-1/인간 에스트로겐 수용체 융합단백질 및 암을 치료하기 위한 그의 용도 |
WO2002076469A1 (en) * | 2001-03-27 | 2002-10-03 | Baylor College Of Medicine | A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity |
DE10127572A1 (de) * | 2001-05-30 | 2002-12-05 | Pathoarray Gmbh | Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen |
US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
DE60233744D1 (de) * | 2001-09-20 | 2009-10-29 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests |
US20030124127A1 (en) * | 2001-12-06 | 2003-07-03 | Lijun Yang | Targeting leukemia cells |
KR100885008B1 (ko) | 2002-02-04 | 2009-02-20 | 코릭사 코포레이션 | 신규 면역효과기 화합물 |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US20060147477A1 (en) | 2002-06-11 | 2006-07-06 | Glaxo Group Limited | Immunogenic compositions |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
US20050054496A1 (en) * | 2003-02-25 | 2005-03-10 | Harms Robert E. | Coated weight plates, dumbbells and method of manufacture |
WO2004078035A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
WO2005098037A1 (en) * | 2003-03-07 | 2005-10-20 | Arcturus Bioscience, Inc. | Breast cancer signatures |
US20060265138A1 (en) | 2003-03-14 | 2006-11-23 | David Bowtell | Expression profiling of tumours |
US20040241725A1 (en) * | 2003-03-25 | 2004-12-02 | Wenming Xiao | Lung cancer detection |
US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US7640114B2 (en) * | 2003-05-21 | 2009-12-29 | The Wistar Institute Of Anatomy & Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
EP1631689A2 (en) * | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
KR101126560B1 (ko) | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | 약제 반응 예측 방법 |
WO2005001138A2 (en) * | 2003-06-18 | 2005-01-06 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
EP1640458B1 (en) * | 2003-06-27 | 2011-12-28 | International Institute of Cancer Immunology, Inc. | Method of selecting patients suitable for wt1 vaccine |
ES2311852T3 (es) * | 2003-08-28 | 2009-02-16 | Ipsogen | Identificacion de un modelo especifico de la expresion del gen erbb2 en cancer de mama. |
JP2007507243A (ja) | 2003-10-03 | 2007-03-29 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 遺伝子発現プロファイルおよび使用方法 |
WO2005044999A2 (en) * | 2003-11-05 | 2005-05-19 | New England Medical Center Hospitals, Inc. | Treatment with immunoregulatory t cells |
WO2005054496A1 (ja) * | 2003-12-02 | 2005-06-16 | Orient Cancer Therapy Co., Ltd. | 細胞動態の検査方法 |
WO2005059543A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963) |
CN1918305B (zh) * | 2004-02-09 | 2010-12-01 | 扶桑药品工业株式会社 | 核酸检测方法及其应用 |
US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
US7332281B2 (en) * | 2004-04-27 | 2008-02-19 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
EP1782070B1 (en) * | 2004-06-17 | 2010-09-08 | MannKind Corporation | Tumor-associated antigen profiles in cancer diagnostics and immunotherapy |
US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
WO2006056304A2 (en) * | 2004-11-23 | 2006-06-01 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
BRPI0518734A2 (pt) | 2004-11-30 | 2008-12-02 | Veridex Llc | prognàstico de cÂncer de pulmço |
US20070059720A9 (en) * | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
WO2006073982A2 (en) * | 2004-12-30 | 2006-07-13 | Regents Of The University Of California | Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein |
US7666595B2 (en) | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
GB0504302D0 (en) | 2005-03-02 | 2005-04-06 | Univ Dublin | Markers for melanoma |
WO2006103442A2 (en) | 2005-04-01 | 2006-10-05 | Ncc Technology Ventures Pte. Ltd. | Materials and methods relating to breast cancer classification |
JP2008535853A (ja) * | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
EP1869222A4 (en) * | 2005-04-15 | 2010-01-20 | Oncomethylome Sciences S A | METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
EP1910564A1 (en) | 2005-05-13 | 2008-04-16 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
EP1904845A4 (en) * | 2005-07-07 | 2009-11-25 | David E Kohne | IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS |
EP1934599A1 (en) * | 2005-10-11 | 2008-06-25 | Merck Patent GmbH | Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
-
2007
- 2007-05-31 CA CA002653949A patent/CA2653949A1/en not_active Abandoned
- 2007-05-31 MX MX2008015372A patent/MX2008015372A/es not_active Application Discontinuation
- 2007-05-31 EP EP11163716A patent/EP2390364A1/en not_active Withdrawn
- 2007-05-31 EP EP11163271A patent/EP2390361A1/en not_active Withdrawn
- 2007-05-31 EP EP11163261A patent/EP2390358A1/en not_active Withdrawn
- 2007-05-31 EP EP11162326A patent/EP2390355A1/en not_active Withdrawn
- 2007-05-31 EP EP11163726A patent/EP2390369A1/en not_active Withdrawn
- 2007-05-31 EP EP07725789A patent/EP2032719A2/en not_active Withdrawn
- 2007-05-31 JP JP2009512510A patent/JP2009538607A/ja active Pending
- 2007-05-31 PE PE2007000676A patent/PE20080742A1/es not_active Application Discontinuation
- 2007-05-31 EP EP11163252A patent/EP2390357A1/en not_active Withdrawn
- 2007-05-31 CL CL200701571A patent/CL2007001571A1/es unknown
- 2007-05-31 EP EP11163719A patent/EP2390366A1/en not_active Withdrawn
- 2007-05-31 EP EP11162325A patent/EP2390354A1/en not_active Withdrawn
- 2007-05-31 EP EP11163264A patent/EP2390360A1/en not_active Withdrawn
- 2007-05-31 EP EP10159376.2A patent/EP2258874B1/en active Active
- 2007-05-31 EP EP11162320A patent/EP2392671A1/en not_active Withdrawn
- 2007-05-31 EP EP11163277A patent/EP2390362A1/en not_active Withdrawn
- 2007-05-31 AU AU2007256383A patent/AU2007256383B2/en not_active Ceased
- 2007-05-31 US US12/303,213 patent/US20100021424A1/en not_active Abandoned
- 2007-05-31 EP EP11163722A patent/EP2390368A1/en not_active Withdrawn
- 2007-05-31 EP EP11163717A patent/EP2390365A1/en not_active Withdrawn
- 2007-05-31 WO PCT/EP2007/004915 patent/WO2007140958A2/en active Application Filing
- 2007-05-31 EA EA200802242A patent/EA200802242A1/ru unknown
- 2007-05-31 EP EP11163268A patent/EP2392675A1/en not_active Withdrawn
- 2007-05-31 EP EP11163263A patent/EP2390359A1/en not_active Withdrawn
- 2007-05-31 EP EP11162324A patent/EP2390353A1/en not_active Withdrawn
- 2007-05-31 EP EP11162327A patent/EP2390356A1/en not_active Withdrawn
- 2007-05-31 EP EP11163713A patent/EP2390363A1/en not_active Withdrawn
- 2007-05-31 EP EP11163720A patent/EP2390367A1/en not_active Withdrawn
- 2007-05-31 EP EP11162329A patent/EP2392673A1/en not_active Withdrawn
- 2007-05-31 AR ARP070102352A patent/AR061136A1/es not_active Application Discontinuation
- 2007-05-31 KR KR1020087031950A patent/KR20090017655A/ko not_active Application Discontinuation
- 2007-05-31 ES ES10159376.2T patent/ES2539042T3/es active Active
- 2007-05-31 EP EP11162323A patent/EP2392672A1/en not_active Withdrawn
- 2007-05-31 BR BRPI0712497-0A patent/BRPI0712497A2/pt not_active IP Right Cessation
- 2007-05-31 TW TW096119645A patent/TW200817680A/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080742A1 (es) | Perfil genico y procedimiento de identificacion | |
EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
CY1120096T1 (el) | Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια | |
ATE466084T1 (de) | Hla-a24-restringiertes krebsantigenpeptid | |
MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
PH12014502507A1 (en) | Anti-angiogenesis therapy for the treatment of breast cancer | |
CR9315A (es) | Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia | |
TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
PL2733493T3 (pl) | Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu | |
AR102538A1 (es) | Métodos de selección de la línea celular t y donante de la misma para la terapia adoptiva celular | |
EP3064584A3 (en) | Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer | |
EP2228072A4 (en) | CANCER VACCINE COMPOSITION | |
HK1148783A1 (zh) | 用於***腺的預後的基因表達標記 | |
CY1120175T1 (el) | Ανταγωνιστες υποδοχεα clever-1 για αποκλεισμο των ανοσο-ανασταλτικων μακροφαγων τυπου 2 | |
EP3299387A3 (en) | Identification of tumor-associated markers for diagnosis and therapy | |
EA201400710A1 (ru) | Способы детекции признаков заболеваний или состояний в жидкостях организма | |
AR054536A1 (es) | Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer | |
WO2010056351A3 (en) | Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia | |
EA201171451A1 (ru) | Генетические маркеры, ассоциированные с ответом на интерферон-альфа | |
EP2527466A3 (en) | Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2009043908A3 (en) | Novel marker genes for regulatory t cells from human blood | |
ATE530668T1 (de) | Verfahren und kits zur brustkrebsprognose | |
MX2021000853A (es) | Vacunas individualizadas para el cancer. | |
BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf | |
CY1116914T1 (el) | ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |